Merrimack Pharmaceuticals, Inc. Director Acquires 249,375.00 in Stock
MACKDelisted Stock | USD 11.96 0.12 1.01% |
About 50% of Merrimack Pharmaceuticals' institutional investors are presently thinking to get in. The analysis of current outlook of investing in Merrimack Pharmaceuticals suggests that some traders are interested regarding Merrimack Pharmaceuticals' prospects. Merrimack Pharmaceuticals' investing sentiment shows overall attitude of investors towards Merrimack Pharmaceuticals.
Merrimack |
Merrimack Pharmaceuticals, Inc. Director Eric Andersen bought 21,875 shares of the firms stock in a transaction that occurred on Friday, January 27th. The stock was acquired at an average price of 11.40 per share, for a total transaction of 249,375.00. Following the transaction, the director now owns 1,263,103 shares in the
Read at thelincolnianonline.com
Merrimack Pharmaceuticals Fundamental Analysis
We analyze Merrimack Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Merrimack Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Merrimack Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Merrimack Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Merrimack Pharmaceuticals Related Equities
PBYI | Puma Biotechnology | 3.97 | ||||
AGIO | Agios Pharm | 2.76 | ||||
FOLD | Amicus Therapeutics | 1.54 | ||||
CLDX | Celldex Therapeutics | 4.90 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |